Teva's migraine drug succeeds in late-stage study

Studio shot of a mature man looking stressed out against a gray backgroundhttp://195.154.178.81/DATA/istock_collage/a3/shoots/785270.jpg (shapecharge)

Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine met the main goal in a late-stage study.

Patients treated with the drug, fremanezumab, experienced a statistically significant reduction in the number of monthly headache days over the 12-week period for both monthly and quarterly dosing regimens, the company said.